It is time to change the way we manage mild asthma: an update in GINA 2019
Abstract Asthma is a heterogeneous lung disease, usually characterised by chronic airway inflammation. Although evidence-based treatments are available in most countries, asthma control remains suboptimal, and asthma-related deaths continue to be an ongoing concern. Generally, it is believed that between 50 to 75% of patients with asthma can be considered as having mild asthma. Previous versions of Global Initiative for Asthma (GINA) suggested that mild asthma in adults can be well managed with either reliever medications, for example, short-acting beta2 agonists (SABA) alone or with the addit... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2019 |
Reihe/Periodikum: | Respiratory Research, Vol 20, Iss 1, Pp 1-6 (2019) |
Verlag/Hrsg.: |
BMC
|
Schlagwörter: | Global Initiative for Asthma (GINA) / Mild asthma / Symptom-driven / Short-acting β2 agonists (SABA) overuse / Diseases of the respiratory system / RC705-779 |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-27249689 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://doi.org/10.1186/s12931-019-1159-y |